Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
What Doximity (NYSE: DOCS) CFO resignation means for governance, capital allocation, and investor confidence
Read More Pharma Industry News Poxel wraps up enrollment in DESTINY-1 phase 2 trial for PXL065 in NASH Poxel, a French biopharma company, has wrapped up patient enrollment for the phase 2 DESTINY-1 clinical trial, which… bySrinathOctober 9, 2021